These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Autoimmune aspects of treatment with TNF-alpha inhibitors]. Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135 [TBL] [Abstract][Full Text] [Related]
6. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424 [TBL] [Abstract][Full Text] [Related]
7. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Ollendorf DA; Klingman D; Hazard E; Ray S Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156 [TBL] [Abstract][Full Text] [Related]
8. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Kooloos WM; de Jong DJ; Huizinga TW; Guchelaar HJ Drug Discov Today; 2007 Feb; 12(3-4):125-31. PubMed ID: 17275732 [TBL] [Abstract][Full Text] [Related]
10. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. Barra L; Pope JE; Payne M J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267 [TBL] [Abstract][Full Text] [Related]
11. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997 [TBL] [Abstract][Full Text] [Related]
12. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. Davies A; Cifaldi MA; Segurado OG; Weisman MH J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363 [TBL] [Abstract][Full Text] [Related]
14. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis]. Lanfant-Weybel K; Lequerré T; Vittecoq O Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945 [TBL] [Abstract][Full Text] [Related]
15. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540 [TBL] [Abstract][Full Text] [Related]
16. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191 [TBL] [Abstract][Full Text] [Related]
17. TNF-α antagonists beyond approved indications: stories of success and prospects for the future. Karampetsou MP; Liossis SN; Sfikakis PP QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008 [TBL] [Abstract][Full Text] [Related]
18. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. Carter CT; Changolkar AK; Scott McKenzie R J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788 [TBL] [Abstract][Full Text] [Related]
19. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases. Famenini S; Wu JJ J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169 [TBL] [Abstract][Full Text] [Related]
20. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept). Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]